2 newsletters, ranked by editorial quality and how recently they published. Looking for something more specific? Search instead.
Alex Kesin's blog-style newsletter examines biotech and drug development, from US-China competition in drug licensing to pharma share buybacks and the heavy-tailed revenue distributions shared by drugs and Hollywood films. Readers get long-form, opinionated analysis with data, historical context and wry commentary on industry dynamics.
Vital Signs is a weekly email covering EU health policy, including EMA drug approvals, pharmaceutical industry competitiveness and EU health programmes. Its issues mostly summarise regulatory and political news from Brussels, with some reporting on industry and public health developments.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
